Web4 jan. 2024 · For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. WebIonis Pharmaceuticals News: This is the News-site for the company Ionis Pharmaceuticals on Markets Insider Menu icon A vertical stack of three evenly spaced horizontal lines.
Ionis Pharmaceuticals News Markets Insider
Web26 jul. 2024 · Ionis is leading the way in treating root causes of many neurological diseases and developing antisense medicines for common diseases like Alzheimer's and Parkinson's as well as rare diseases like amyotrophic lateral sclerosis (ALS) and Alexander disease. Web20 mrt. 2024 · FDA Releases Briefing Docs for Upcoming Biogen/Ionis Tofersen Adcomm. Biomarkers as a surrogate endpoint in ALS will go on trial March 22 as Biogen and … china was founded in 1949
Ionis reports first quarter financial results and recent business ...
WebKrijg gedetailleerde informatie over het Ionis Pharmaceuticals Inc (IONS) Aandeel inclusief Prijs, Grafieken, Technische Analyses, Historische gegevens, Ionis Pharma Rapporten … Web23 jan. 2024 · The FDA announced that a panel of experts is scheduled to meet on Mar. 22 to discuss the marketing application for tofersen, a treatment for neurodegenerative … WebIonis Pharmaceuticals Inc Notizie. Gli EPS di Ionis Pharma hanno battuto le aspettative per 0,55$, il fatturato appena sotto le previsioni. Da Investing.com -. Investing.com - Ionis Pharma (NASDAQ: IONS) ha riportato nel quarto trimestre utili per azione di -0,37 $, 0,55$ sopra le stime degli analisti di -0,92$. china washable bathroom rugs